GlobalData

GlobalData survey uncovers stark regional differences in physician support for patient involvement in choosing between biologics…

GlobalData analyst highlights Leqselvi’s high-dose advantage and renewed market entry as key drivers for swift adoption, despite…

While prasinezumab missed its primary endpoint, time-to-event analyses suggest potential in delaying early Parkinson’s disease…

This new fund is part of a series of supportive steps Japan took over the past few years to enhance its pharmaceutical sector…

GlobalData’s report reveals that CGT market for GI disorders, as a standalone therapy area, is expected to increase from $47…

GlobalData’s bio/pharmaceutical outsourcing report highlights the reliance of smaller pharma companies on CDMOs for production,…

CRD-38’s alternative mechanism positions it as a potential new option in heart failure treatment

Sionna’s IPO signals investor interest amid competitive cystic fibrosis treatment landscape

Targeted therapies poised to transform Fragile X syndrome market with 4X growth by 2030

Oral eosinophilic asthma therapy nears Phase 3 completion, with results set to shape future treatment pathways